Background: Coumarin group antibiotics, such as novobiocin, coumermycin A 1 and clorobiocin, are potent inhibitors of DNA gyrase. These antibiotics have been isolated from various Streptomyces species and all possess a 3-amino-4-hydroxycoumarin moiety as their structural core. Prior labeling experiments on novobiocin established that the coumarin moiety was derived from L-tyrosine, probably via a L-hydroxy-tyrosine (L-OH-Tyr) intermediate. Recently the novobiocin gene cluster from Streptomyces spheroides was cloned and sequenced and allows analysis of the biosynthesis of the coumarin at the biochemical level using overexpressed and purified proteins.
Introduction
The coumarin group of antibiotics, such as novobiocin, clorobiocin and coumermycin A 1 (Fig. 1A) , are secondary metabolites from certain Streptomyces species and exert their antibacterial activity by inhibition of the type II DNA topoisomerase DNA gyrase [1^4] . These inhibitors have a 3-amino-4-hydroxy-coumarin and a substituted deoxysugar noviose as a common core that is essential for their biological activity. Clorobiocin di¡ers from novobiocin in that the methyl group at the C-8 of coumarin ring is replaced by a chlorine atom, and the carbamoyl at the C-3P of the noviose is substituted by a 5-methyl-2-pyrrolcarboxyl group. Coumermycin A 1 contains two of the coumarin^noviose core joined by a 3-methyl-2,4-dicarboxyl pyrrole linker and has the same substituted noviose as in clorobiocin. Gyrase inhibitors, including the structurally similar quinolones [5] , block DNA replication, induce SOS repair systems and eventually cause bacterial cell death. Previous kinetic and structural studies [3, 4, 6, 7] have shown that coumarin group antibiotics are competitive inhibitors of ATP binding to the gyrase B subunit. Substitution of a 3P-noviose carbamoyl (novobiocin) for a 5-methyl-2-pyrrolcarboxyl group (clorobiocin) results in an enhanced inhibitory activity toward gyrase in vitro [8] . Coumermycin A 1 , on the other hand, acting like a novobiocin dimer, stabilizes a dimer form of the 43 kDa fragment of GyrB [9] . Early labeling studies have established that the substituted coumarin and the prenylated benzoic acid moieties were derived from L-Tyr while the noviose was from glucose [10^12] . Recently, insights into the biosynthesis of novobiocin were obtained by the sequencing of the nov gene cluster from Streptomyces spheroides [13] . As shown in Fig. 1B , it is possible that L-hydroxy-tyrosine (L-OH-Tyr) could be a common precursor of both substituted coumarin and benzoyl moieties. An amide synthase responsible for joining these two moieties has been puri¢ed and characterized very recently [14] .
The de¢ned nov genes in the novobiocin cluster [13] provide a chance to elucidate some key steps for novobiocin assembly in vitro. We focused on delineating the enzymes that create the coumarin ring sca¡old. In this work we have investigated two adjacent open reading frames (ORFs) in the nov cluster, NovH and NovI, to establish their role in tyrosine activation and modi¢cation in the coumarin-forming pathway. Sequence homology analysis suggested NovH is related to amino acid activating modules of non-ribosomal peptide synthetases (NRPSs) in having two predicted domains, an amino acid adenylating (A) domain and an aminoacyl-tethering peptidyl carrier protein (PCP) domain [15^17] . The second protein, NovI, has similarities to subclasses of cytochrome P450 monooxygenases [13,18^20] . Here we report that NovH activates LTyr and forms a tyrosyl-S-NovH acyl-S-enzyme that is the substrate for regio and stereospeci¢c hydroxylation by NovI to yield a L-OH-tyrosyl group still tethered on the NovH PCP domain. 
Results

Expression and puri¢cation of S. spheroides NovH and NovI in Escherichia coli
Two enzymes that may be responsible for the initial steps in the biogenesis of the coumarin ring in novobiocin were expressed and puri¢ed. NovH is a didomain NRPS with a putative L-tyrosine speci¢c A domain and a C-terminal PCP domain while NovI shows signi¢cant sequence homology to cytochrome P450 hydroxylases. E. coli BL21(DE3) cells harboring NovH expression constructs grown at temperatures above 30³C after induction yielded only insoluble protein. To obtain soluble protein, cells were cooled to 24³C before induction with 50 WM of isopropyl L-D-thiogalactopyranoside (IPTG). A C-terminal His6-tagged NovH was puri¢ed by nickel a¤nity chromatography in apo-form with a protein yield of 30 mg/l. NovI was expressed as inclusion bodies when grown above 20³C, but soluble protein was obtained by growing at 15³C for 72 h without IPTG induction. NovI was puri¢ed as an N-terminal His10-tagged fusion protein by nickel chelate chromatography with a protein yield of 5 mg/l of culture. Both proteins were puri¢ed to near homogeneity with a correct molecular weight as judged by SDS^PAGE ( Fig. 2A) . As shown in Fig. 2B , the UV^visible spectrum of the puri¢ed NovI indicates that NovI was fully loaded with the heme cofactor. 3 . Schematic representation of the proposed functions of NovH. NovH isolated from E. coli needs to be primed by a PPTase with CoA to become a holo-protein by installing a prosthetic P-pant group at the active site Ser561 on the PCP domain [13] . The A domain activates L-Tyr as L-tyrosyl-AMP and then transfers the L-tyrosyl group to the HS-pant-PCP domain of NovH through thioester formation.
Characterization of NovH as a L-
rounded by a canonical sequence ( 549 DVRSNFFE-MGGNSILAVDL 567 ) for posttranslational priming [13] . Puri¢ed NovH protein was assayed for covalent attachment of a phosphopantetheinyl (P-pant) group by Sfp [21] , a phosphopantetheinyltransferase (PPTase) from surfactin synthetase from Bacillus subtilis (Fig. 3) . Under the assay conditions, Sfp rapidly ( 6 3 min) modi¢ed the NovH with [ 3 H]CoA as substrate (data not shown) [21, 22] . The percentage of P-pant incorporation was estimated to be s 95% based on the speci¢c radioactivity of [ 3 H]CoA and the concentration of NovH. Thus, NovH was puri¢ed as an apo protein from E. coli, typical for other heterologously expressed NRPS PCP domains [23] , but could be converted fully to the holo-PCP form by Sfp in vitro.
A domain selectivity of NovH
The A domain of an NRPS is expected to be bifunctional, i.e. activation of the amino acid substrate and subsequent ligation of aminoacyl-AMP to the downstream holo-PCP domain, as depicted in Fig. 3 . The activity of the NovH A domain, aminoacyl adenylate formation, was assayed by a substrate-dependent ATP^ [ 32 P]PPi exchange reaction. The relative activities of the amino acid substrates tested are displayed in Fig. 4 . The NovH A domain was selective for both the chirality of K-carbon and properties of the side chain group. Only L-Tyr served as a competent substrate for the NovH A domain. While DTyr, Gly, L-Trp, 3-methyl-L-Tyr, and (2S,3R)-L-OH-Tyr were essentially inactive, L-Ala, L-Phe, 3-chloro-L-Tyr, and p-bromo-DL-Phe had marginal activities with an apparent k obs of 1.0^4.5% relative to L-Tyr (Fig. 4) . The kinetic parameters of the ATP^PPi exchange assays of several amino acids are summarized in Table 1 32 P]PPi exchange assays. L-phenyl-Gly, L-p-OHphenyl-Gly, p-OH-phenyl-acetate, and p-OH-phenyl-pyruvate were also examined and all of them failed to show any detectable activity (data not shown). inforcing the evidence that NovH was puri¢ed in the apoprotein form. A time course of NovH covalent auto-aminoacylation is shown in Fig. 5C . Under the conditions used for the assays, self-aminoacylation was a rather slow process and it took V50 min to plateau at a ¢nal stoichiometry of 0.55 equivalent of L-Tyr-S-NovH. a cytochrome P450 monooxygenase that hydroxylates the L-carbon of the tethered L-tyrosyl group on NovH. The native electron donating proteins of S. spheroides are yet to be cloned, so commercially available spinach ferredoxin and ferredoxin reductase were used in the NovI incubations. In the incubation shown in Fig. 7B , a ratio of 4:1 for NovH:NovI was used and the incubation proceeded for 2 h at 24³C. No radioactive species other than starting [ 3 H]L-Tyr was detected in solution. To evaluate any product covalently bound to NovH, compounds were released from NovH by KOH treatment to hydrolyze the aminoacyl-S-PCP thioester linkage and analyzed by reversephase high performance liquid chromatography (RP-HPLC) and scintillation counting. The radioactivity of fractions (1 ml in size) was plotted versus retention time (rt) to give Fig. 7B , while Fig. 7A shows the analysis of the identical reaction carried out in the absence of NovI. The released radioactive compound (rt = 21.5 min) from the control reaction (Fig. 7A ) was identi¢ed to be [
Characterization of NovI as a cytochrome P450 monooxygenase that hydroxylates L-tyrosyl-S-
3 H]L-Tyr, as established by co-injection (data not shown). In the reaction containing NovI, a much smaller substrate LTyr peak (rt = 21.5 min) was presented, however, two new peaks with rts of 7.8 and 25.8 min were observed (Fig. 7B) . The identity of ¢rst radioactive peak (rt = 7.8 min) was initially established as L-L-OH-Tyr by co-elution with unlabeled authentic L-OH-Tyr added as carrier and monitored by UV (at 230 nm). In addition to the 7.8 min L-OH-Tyr peak, the HPLC UV chromatogram also detected another product peak that co-eluted with the 25.8 min radioactive peak, indicating this UV-active peak was likely derived from the added non-labeled carrier L-OHTyr. The KOH treatment during chemical release of the covalently tethered compound could promote a retro aldol reaction breaking down L-OH-Tyr to 4-OH-benzaldehyde, a process illustrated in Fig. 7C . Since the tritium label is at positions 3 and 5 of the phenyl ring of the input substrate [ 3 H]L-Tyr, the L-OH-Tyr breakdown product 4-OH-benzaldehyde will be tritiated. Co-injection of the incubation products with authentic 4-OH-benzaldehyde (Sigma) con¢rmed the comigration of the 25.8 min radioactive peak (data not shown).
A large-scale incubation with 60 nmol of NovH allowed isolation of enough products for mass characterization. The two product peaks were collected following RP-HPLC separation, lyophilized and subjected to matrix-assisted laser desorption ionization time-of-£ight mass spectroscopy (MALDI-TOF MS) analysis. The measured masses of 198.1 and 122.1 (M+H mode) matched well with the predicted values of L-OH-Tyr (C 9 H 11 NO 4 , calc. 197.1) and 4-OH-benzaldehyde (C 7 H 6 O 2 , calc. 122.0).
Properties of the NovI mediated hydroxylation
reaction To see if product formation catalyzed by NovI is proportional to the amount of substrate used, a series of incubations with varying amounts of [ 3 H]L-tyrosyl-S-NovH were performed and analyzed. A linear correlation of the amounts of product (L-OH-Tyr plus the breakdown product 4-OH-benzaldehyde) and the substrate protein NovH was observed (Fig. 8A) .
As shown in Fig. 8B , when the amount of NovH was ¢xed at 3.1 nmol, and NovI was titrated down from 240 to 12 pmol, multiple turnovers on NovI were observed. At the 12 pmol lower limit, NovI displayed up to 55 turnovers towards its partner substrate protein L-Tyr-S-NovH. This result clearly demonstrates that NovH and NovI re- 3 H]L-tyrosyl-S-NovH/ NovI incubation products released by KOH treatment. At the end of incubation, the proteins were precipitated with 10% TCA and the protein pellets was washed with water to remove soluble small molecules. Then 0.1 M KOH was added to redissolve protein pellets and the resultant solution was incubated for 5 min at 60³C to hydrolyze the aminoacyl thioester linkage to NovH. Fractions (1 ml) from the RP-HPLC separation were collected and the radioactivity was measured by liquid scintillation counting. See Section 5 for detailed conditions. (A) Plot of radioactivity of the fractions versus rt (or fraction number) from the RP-HPLC analysis of the control reaction in which NovI was withdrawn. The released radioactive compound (rt = 21.3 min) was proven to be Although the newly generated chiral center of L-OH-
Tyr is lost at a later stage in coumarin biosynthesis (Fig.  1) , it is still of interest to examine if the hydroxylation reaction e¡ected by NovI is stereospeci¢c and to establish the absolute stereochemistry. As shown in Fig. 9 , the RP-HPLC-puri¢ed NovI product, [ 3 H]L-OH-Tyr, had the same rt (18.4 min) as chemically prepared (2S,3R)-L-OHTyr (Fig. 9 , trace C versus trace A) when analyzed by chiral HPLC (Daicel ChiralPAK WH 0 ) [24, 25] . Under the operating conditions, the (2R,3S) isomer (rt = 9.8 min) was well resolved from the (2S,3R) isomer (Fig. 9,  trace B) . Chiral HPLC analysis clearly indicated that the newly generated chiral center is an R center and that NovI makes a (2S,3R)-3-OH-Tyr-S-NovH covalent acyl enzyme.
Discussion
The results reported in this work establish enzymatic activities for the two proteins NovH and NovI from the novobiocin biosynthetic cluster and showed that aminoacylated NovH is a hydroxylation substrate for NovI. The bioinformatic-based predictions of an A and PCP domain in NovH [16] were validated with the puri¢ed enzyme. The A domain is speci¢c for L-tyrosine, as assessed by an amino acid-dependent ATP^[
32 P]PPi exchange assay which monitors reversible formation of tyrosyl-AMP. The apo-PCP domain of NovH must be primed by covalent posttranslational phosphopantetheinylation. A dedicated PPtase for the nov cluster has not yet been identi¢ed so we used the broad speci¢city PPTase Sfp from the surfactin synthetase cluster of Bacillus [21] (Fig. 7B) . The right Y-axis in dpm is for plot C. rosine to detect and quantitate the mole fraction of NovH accumulating as L-tyrosyl-S-NovH.
When the proposed companion protein NovI was puri¢ed it was red and contained one equivalent of heme cofactor. When provided with a heterologous electron donor system, spinach ferredoxin reductase and ferredoxin (the S. sphaeroides electron transfer proteins are yet to be cloned), to transfer electrons from NADPH, NovI utilized O 2 and performed as a catalytic monoxygenase. Initial assays indicated that NovI would not oxygenate free tyrosine or the soluble thioester surrogate L-tyrosyl-S-N-acetyl cysteamine (data not shown). Thus, NovI recognizes the Ltyrosyl moiety presented on the pantetheinyl arm of the PCP domain of NovH. NovI acts catalytically on its tyrosyl-S-NovH partner but the L-OH-Tyr product stays covalently tethered on the NovH PCP domain. To identify the L-OH-K-amino acid product, KOH was added to cleave the thioester linkage and thus allowed determination of the identity and stereochemistry of the L-hydroxylation product.
The question arises why NovI is speci¢c for hydroxylation of the benzylic carbon of tyrosine tethered as a thioester on a partner protein. One answer comes from inspection of the structure of the coumarin ring B moiety of novobiocin. The coumarin is a two-ring lactone and the mechanism of lactonization has been inferred by 18 O labeling studies to be attack of the carboxyl oxygen on the aryl ring of Tyr in an oxidative cyclization [11] . However, 18 O enrichment of the ring oxygen was quite low (V0.078 at% excess) in that study and we favor a distinct pathway of lactonization, based on our enzymatic results and putative functions of other ORFs in the nov cluster. Here we propose that the ring oxygen likely arises from hydroxylation by a predicted £avoprotein monoxygenase NovC (Fig. 10) . Lactone formation would then arise by intramolecular capture of the proposed 2,4-dihydroxy-3-methyl-L-ketoTyr-S-PCP of NovH as shown in Fig. 10 . This is closely analogous to the intramolecular lactonizing step in 6-deoxyerythronolide biosynthesis [26] and in fengycin [27] biosynthesis by polyketide synthase (PKS) and NRPS assembly lines, respectively. The thermodynamic activation of the thioester moiety makes the cyclization and release from ACP/PCP carrier domains a favorable chain release step. The same logic applies for release of the coumarin from NovH.
This logic for coumarin ring assembly suggests the PCP domain of NovH is a sca¡old on which the L-tyrosyl moiety is ¢rst covalently docked in kinetically stable but thermodynamically activated thioester linkage, and then chemically modi¢ed before cyclization. The pantetheinyl arm is 20 A î long if fully extended and this property may be crucial for providing access to the enzymes that will modify the tyrosyl backbone and ring. The ¢rst of these modi¢cations is now proven to be the L-hydroxylation by NovI. Restriction of NovI activity to a tyrosine covalently tethered to the NovH PCP rather than free tyrosine may have advantages to the antibiotic-producing cell. It would control the fraction of the cellular pool of tyrosine that is hydroxylated and diverted to novobiocin formation. The companion ORFs to NovH and NovI include NovJ and NovK, predicted L-ketoacyl-carrier protein reductases [13] , NovC, the proposed aromatic ring hydroxylating £a- Fig. 10 . Schematic illustration of the proposed pathway of aminocoumarin formation in the biogenesis of novobiocin. The functions of NovH and NovI have been established in this study. Both NovJ and NovK are similar to 3-keto-ACP reductase and they may form a heterodimer and operate in the reverse direction to oxidize 3-OH to 3-keto. NovO is similar to some quinone C-methyltransferases [30, 31] but the timing of methylation is not clear. NovC resembles £avin-dependent monooxygenases (35 and 32% similarity to dimethylaniline and cyclohexanone monooxygenases, respectively) [32, 33] , and is proposed to hydroxylate the ortho position of the phenyl ring. The nucleophilic attack of the ortho hydroxyl group on the thioester carbonyl center would release the coumarin ring and regenerate NovH.
voprotein, and NovO, a predicted SAM-dependent Cmethyltransferase [13] . The action of these three enzymes on L-OH-Tyr-S-NovH, as suggested in Fig. 10 , would produce the 2,4-dihydroxy-3-methyl-L-keto-tyrosyl-SNovH acyl-S-enzyme. Its intramolecular cyclizative capture would regenerate free NovH and yield the released lactone that is the coumarin ring found as the sca¡old in the coumarin group antibiotics. NovJ could act alone to oxidize the L-hydroxyl group, but it is also possible that NovJ and NovK are subunits of single dimeric enzyme or represent two di¡erent isoenzymes. A comparable pair BbsC/BbsD, similar to 3-hydroxyacyl-CoA dehydrogenases, has been implicated in the L-oxidation of benzylsuccinate [28] . The timing of NovC and NovO action is as yet unknown, but our result that 3-methyl-L-Tyr was a very poor substrate for NovH (Table 1) argues that NovO acts downstream of NovH and NovI. The proposed pathway here would represent a novel use of the NRPS-type aminoacyl covalent tethering strategy and suggests that four tailoring enzymes, NovI, J/K, C and O, carry out sequential modi¢cation of a tyrosyl-S-pantetheinyl acyl enzyme.
In terms of maximizing metabolic economy it is possible that the L-OH-Tyr-S-NovH is also the source of the ring A 4-OH-benzoyl moiety of novobiocin. With the enzymically generated L-OH-Tyr and also with authentic samples we have seen facile retro aldol fragmentation across the C2^C3 bond to produce 4-OH-benzaldehyde and glycine. Oxidation of this aldehyde to the acid, perhaps after prenylation, could be e¡ected by an oxidase to provide the ring A fragment of novobiocin.
Finally, a data base search for pairs of ORFs homologous to NovH and NovI that are found clustered together, reveals two other candidates, besides the pair in coumermycin A 1 CumC/CumD [18] , that could analogously be activating amino acids as P-pant thioesters and then carrying out L-hydroxylation. One pair is ORF19 and ORF20 in the chloroeremomycin biosynthetic cluster [19] , which is predicted to be a comparable A^PCP/P450 pair and this glycopeptide antibiotic of the vancomycin family indeed has a heptapeptide sca¡old with (3R)-L-OH-Tyr residues at positions 2 and 6 [19] . In the biosynthetic cluster for the nucleoside antibiotic nikkomycin there is a corresponding A^PCP/P450 pair predicted, NikP1/NikQ, and we would assign NikQ as likely to be a monooxygenase producing a L-OH-His-S-PCP acyl-S-enzyme intermediate. It will be of interest to validate these predictions and see if NovI, CumD, ORF20 and NikQ do indeed form a new subgroup of cytochrome p450 monoxygenases committed to L-hydroxy amino acid formation on a segregated amino acid pool tethered to the PCP domains of partner proteins.
Signi¢cance
The antibacterial agents novobiocin, clorobiocin and coumermycin A 1 all contain a 3-amino-4-hydroxy-coumarin moiety that is a central sca¡old for presentation of these antibiotics to their target, the N-terminal portion of the GyrB subunit of DNA gyrase. The biosynthesis of the bicyclic coumarin platform has been known to occur from tyrosine and presumably proceed through a L-OHTyr intermediate. The recent sequencing of the biosynthetic gene cluster for both novobiocin, and more recently, coumeromycin A 1 , has suggested that two proteins, NovH and NovI, would start the coumarin pathway and represent the ¢rst committed steps to tyrosyl L-hydroxylation. This work validates that the tyrosine molecules for coumarin ring formation are activated and tethered as covalent tyrosyl-S-NovH acyl enzyme species on the PCP domain of NovH, and that this tyrosine pool is the speci¢c substrate for the partner enzyme NovI, a cytochrome P450 monooxygenase. The L-OH-Tyr-S-NovH product from NovI action is proposed to be a substrate for oxidation, cyclization and concomitant release of the 3-amino-4-hydroxy-coumarin from the NovH PCP domain. Homologs of the NovH/NovI pairs, found in other microorganisms that produce antibiotics containing L-hydroxyl amino acid moieties, such as the vancomycins and nikkomycins, suggest the hydroxylation of a tethered aminoacyl-S-PCP may be a general strategy for diversion of a fraction of the amino acid pool to modi¢cations that provide building blocks for antibiotic biosynthesis.
Materials and methods
Cloning of novH and novI genes
The novH and novI genes of the novobiocin cluster were ampli¢ed from S. spheroides (ATCC26935) genomic DNA by polymerase chain reaction. Primers NovH-NtermNdeI (5P-GGA AGG CAT ATG TTC AAC ACT CGT GCG AAC AA-3P) and NovH-CtermXhoI (5P-GCC TTC CTC GAG CTC CTC CAG GGT CGC TAT-3P) were used to amplify the novH gene. The novI gene was ampli¢ed with primers NovI-NtermNdeI (5P-CCG ATA CAT ATG AGC ACC CGT CCG ACC GTG-3P) and NovI-NtermXhoI (5P-GGG TAA CTC GAG GCC CGT GAT CCT GAT CGG-3P). The introduced NdeI and XhoI restriction sites of each primer are highlighted with boldface type. The ampli¢ed products were gel-puri¢ed, digested with NdeI and XhoI restriction enzymes, and ligated into pET24b and pET16b to give NovH C-terminal His6-tagged and NovI N-terminal His10-tagged constructs, respectively. The resulting plasmids, pHC10 and pHC21, were transformed into E. coli BL21(DE3) for protein overexpression.
Overexpression and puri¢cation of NovH and NovI proteins
Cells harboring pHC10 plasmid were grown in LB medium supplemented with 40 Wg/ml kanamycin. The cells were grown at 37³C to an OD 600 of 0.6, cooled to 24³C, induced with 50 WM of IPTG and allowed to grow for an additional 6 h at 24³C. Growth of pHC21/BL21(DE3) involved inoculating 1 l of LB medium containing 100 mg ampicillin, 50 mg FeCl 3 and 50 mg N-aminolevulinic acid with 10 ml of overnight culture, and was continued for 3 days at 15³C without IPTG induction. The cells from each 6U1 l culture were harvested by centrifugation (10 min at 6000Ug) and resuspended in 70 ml of bu¡er A (20 mM Tris^Cl, 0.2 M NaCl, 5 mM imidazole, pH 8.0). Resuspended cells were broken by French Press (two passages at 15 000 psi) and the cell debris was removed by centrifugation (30 min at 35 000Ug). The supernatant was incubated with 4 ml of super£ow nickel resin (Qiagen) for 2 h at 4³C. The resin was then packed into a column, washed with 20 bed volumes of wash bu¡er (bu¡er A plus 20 mM imidazole), and the protein was eluted by a linear gradient of 20^150 mM imidazole. Fractions containing the protein (judged by SDS^PAGE) were pooled, dialyzed against bu¡er B (20 mM Tris^Cl, 50 mM NaCl, 1 mM dithiothreitol, 10% glycerol, pH 7.5), concentrated, £ash frozen in liquid nitrogen and stored at 380³C. Concentrations of the puri¢ed NovH and NovI were measured spectrophotometrically at 280 nm using the calculated extinction coe¤cient of 0.031 and 0.061 WM 31 cm 31 for NovH and NovI, respectively.
Posttranslational modi¢cation of the NovH PCP domain with Sfp
A TCA precipitation assay [22] was adopted to measure the time course and the stoichiometry of the apo to holo conversion of NovH using B. [24] was added during the work-up as a non-labeled carrier compound. The proteins were removed by acidifying the mixture with 5 Wl of 50% TFA followed by centrifugation. Prod-uct formation was analyzed by HPLC using a Vydac1 C18 small pore analytical column (5 Wm, 4.6U250 mm) at 1 ml/min £ow rate with monitor setting at 230 nm. The elution pro¢le started with 100% solvent A (A = H 2 O, 0.1% TFA) for 10 min, followed by a linear gradient from 0 to 50% solvent B (B = acetonitrile, 0.1% TFA) over 15 min. The radioactivity of fractions (1 ml) was measured by liquid scintillation counting of the collected samples. Plots of radioactivity versus fraction number were used to determine the rt of the product. A control incubation was carried out in parallel under the same conditions except that NovI was omitted.
Mass analyses of the NovI reaction products released from NovH
A large-scale incubation (2 ml) contained 75 mM Tris^Cl (pH 7.5), 50 mm NaCl, 5 mM MgCl 2 , 3 mM ATP, 5 mM TCEP, 1.5 mM NADPH, 1 mM L-Tyr, 40 WM of holo NovH, 5 WM NovI, 5 WM ferredoxin and 0.4 U ferredoxin reductase. Incubation proceeded for 1 h at 24³C for aminoacylation of NovH with L-Tyr prior to the addition of NovI, NADPH and the electron transfer proteins to initiate hydroxylation. The work up procedure noted above for radioactive incubations was followed. Two peaks that possessed the same rt as the (2S,3R)-L-OH-Tyr and 4-OH-benzaldehyde (Sigma) standards were collected from RP-HPLC, lyophilized and subjected to MALDI-TOF MS analysis.
Properties of the NovI mediated hydroxylation reaction
To examine whether NovI catalyzed product formation in a substrate-dependent fashion, a series of incubations (200 Wl) were carried out. Incubation mixtures contained 75 mM TrisĈ l (pH 7.5), 5 mM MgCl 2 , 0.5 mM [ 3 H]L-Tyr (90 Ci/mol), 2 mM ATP, 2 mM TCEP, 1 mM NADPH, 5 Wm ferredoxin, 0.1 U ferredoxin reductase, 10 WM NovI, and various concentrations (5^80 WM) of the holo NovH. After covalent loading of L-Tyr achieved by incubating at 24³C for 1.5 h, NovI and other necessary components were added to initiate the L-hydroxylation reaction. Reactions were terminated after 2 h at 24³C with 10% TCA. Work up and product analysis followed the procedure described above. In another experiment, catalytic amounts (ranging from 0.048 to 0.96 WM in 250 Wl of reaction mixture) of NovI were used in the incubations while the concentration of NovH was kept at 12.4 WM. Reactions were worked up and analyzed after 4 h incubation at 24³C.
Determination of the chirality of the L-OH center introduced by NovI
An incubation was carried out to prepare [ 3 H]L-OH-Tyr following procedures described above. The pure product was obtained by RP-HPLC separation followed by lyophilization. The stereochemistry of the L center was established by chiral HPLC analysis with a ChiralPAK WH 0 column (Daicel) compared with chemically prepared reference samples of (2S,3R)-3-OH-Tyr [24] and racemic threo isomers (2S,3R)-and (2R,3S)-3-OH-Tyr [29] .
Isocratic elution at 1 ml/min £ow rate of 2.5 mM CuSO 4 was used. Fractions (0.5 ml) were collected and measured for radioactivity by a liquid scintillation counter to determine the rt of the enzymatic product. When analyzing unlabeled reference compounds, their rts were measured by monitoring at 272 nm with an UV-detector.
